Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report
Oligodendroglioma is defined by IDH mutation and 1p/19q codeletion. Normal TP53 status is also its molecular feature. We report a case of oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation at recurrence after temozolomide therapy. The primary and recurrent tumors shared I...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
12. August 2020
|
| In: |
Acta neurochirurgica
Year: 2020, Volume: 162, Issue: 12, Pages: 3019-3024 |
| ISSN: | 0942-0940 |
| DOI: | 10.1007/s00701-020-04514-3 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00701-020-04514-3 Verlag, lizenzpflichtig, Volltext: https://link.springer.com/article/10.1007/s00701-020-04514-3 
|
| Author Notes: | Takahiro Ono, Annekathrin Reinhardt, Masataka Takahashi, Hiroshi Nanjo, Akihisa Kamataki, Andreas von Deimling, Hiroaki Shimizu |
| Summary: | Oligodendroglioma is defined by IDH mutation and 1p/19q codeletion. Normal TP53 status is also its molecular feature. We report a case of oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation at recurrence after temozolomide therapy. The primary and recurrent tumors shared IDH1 and TERT promoter mutations. Although 1p/19q was codeleted in the primary tumor, it was imbalanced in the recurrent tumor harboring TP53 mutation. The copy-neutral loss of heterozygosity might have imbalanced the 1p/19q codeletion, while temozolomide therapy possibly caused the TP53 mutation. Such phenomena, although rare, should be noted during the clinical treatment of oligodendrogliomas. |
|---|---|
| Item Description: | Gesehen am 27.04.2026 |
| Physical Description: | Online Resource |
| ISSN: | 0942-0940 |
| DOI: | 10.1007/s00701-020-04514-3 |